Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking - 2002 -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (135)	1/6/2002 11:26:37 PM
From: SG	Respond to of 308

Edification is never OT. Especially if it might help make $. SG

To: tom pope who wrote (135)	1/7/2002 8:15:12 AM
From: Arthur Radley	Respond to of 308

This should be a "fun" presentation....ImClone Systems Announces Webcast of Presentation at the JPMorgan H&Q 20th Annual Healthcare Conference NEW YORK--(BW HealthWire)--January 7, 2002--ImClone Systems Incorporated (Nasdaq: IMCL - news) announced today that its presentation to the JPMorgan H&Q 20th Annual Healthcare Conference will be accessible via a live video webcast. Samuel D. Waksal, Ph.D., President and Chief Executive Officer of ImClone Systems, will deliver the presentation at 10:30 A.M. P.S.T. on Wednesday, January 9, 2002 JPMorgan has just downgraded IMCL...stock is already down $4.00 this morning.....something "ain't" right with the story that is being spun by IMCL's CEO. IMO expect a delay in the filing and more trials for the drug. 6:24am 01/07/02 Biotechs Amgen, Gilead upped (AMGN, GILD, GENZ, ABGX, CELG, DYAX, IMCL) By Emily Church Biotechs are drawing brokerage attention Monday. Lehman Brothers lifted price targets a tad on five biotech stocks and upgraded Amgen (AMGN) to a strong buy from a buy. UBS Warburg upped Gilead Sciences (GILD) to a buy "on valuation" and JP Morgan Securities lowered the boom on IM Clone Systems (IMCL) , cutting the stock to market perform after Friday's Cancer Letter details. Amgen was trading at $55.67 in euros, up 5 cents in the pre-open. IMCL was lower, London dealers said. Lehman slightly raised price targets for Genzyme General (GENZ) , Gilead, Dyax (DYAX) , Abgenix (ABGX) and Celegene (CELG) on a re-evaluation of the industry. "After a lackluster 2001 for biotech, we are bullish as the new year begins," Lehman says. "We expect positive news from product launches, anticipated FDA activity and major data announcements."